Kura Oncology (KURA) Cash from Investing Activities (2014 - 2026)

Kura Oncology (KURA) has 13 years of Cash from Investing Activities data on file, last reported at -$24.2 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 76.11% year-over-year to -$24.2 million in Q1 2026; TTM through Mar 2026 was $64.1 million, a 159.52% increase from a year earlier, with the FY2025 full-year figure at -$13.1 million, up 87.11% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$24.2 million, up from -$64.6 million in the prior quarter.
• Over the last five years, Cash from Investing Activities for KURA reached as high as $94.0 million in Q3 2025 and fell as low as -$101.4 million in Q1 2025.
• Historically, Cash from Investing Activities has averaged -$5.3 million across 5 years, with a median of $8.6 million in 2023.
• On a YoY basis, Cash from Investing Activities climbed as much as 432.01% in 2024 and fell as far as 956.65% in 2024.
• Year by year, Cash from Investing Activities stood at -$47.3 million in 2022, then jumped by 189.17% to $42.2 million in 2023, then plunged by 325.04% to -$95.0 million in 2024, then soared by 31.97% to -$64.6 million in 2025, then surged by 62.49% to -$24.2 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$24.2 million in Q1 2026, -$64.6 million in Q4 2025, and $94.0 million in Q3 2025.